Patents
The Company’s glutamine derivative products, manufacturing processes, and C. difficile toxin-blocking drugs are all based on a solid foundation of award winning research and intellectual property developed at the University of Virginia through the collaboration of the University's Pharmacology, Chemistry, and Clinical Labs departments. Additional research has also been conducted in Brazil.
All of the Company’s technology is protected by issued or filed patent disclosures with the following patents currently issued:
US Patent #5,561,111
Stable Glutamine Derivatives for Oral and Intravenous Rehydration and Nutrition Therapy (awarded the Henderson UVA Inventor-of-the-year award.
US Patent #6,649,746
Biological production of stable Glutamine, Poly-glutamine Derivatives in Transgenic Organisms and Their Use for Therapeutic Purposes. Issued November 18, 2003.
US Patent #5,639,750
Method of treating C. difficile and Cholera. Issued June 17, 1997.
US Patents #5,436, 239 and #5,929,095
Method of treating C. difficile and Cholera. Issued July 25, 1995 and July 27,1999.